Loading clinical trials...

COMPLETED

Development of the Virtual Unified Huntington's Disease Rating Scale

NCT05748288•Huntington Study Group

Summary

The Huntington Study Group currently holds the registered trademark for the Unified Huntington's Disease Rating Scale. The UHDRS® is a research tool which has been developed by the HSG to provide a uniform assessment of the clinical features and course of HD. The UHDRS® has undergone extensive reliability and validity testing and has been used as a major outcome measure by the HSG in controlled clinical trials. The purpose of this research study is to determine if a standard HD assessment (the UHDRS®) is as reliable when conducted virtually as it is when conducted at an in-person visit (vUHDRS)

Detailed Description

The UHDRS® is comprised of five components: Motor Assessment Cognitive Assessment Behavioral Assessment Independence Scale Functional Assessment Total Functional Capacity (TFC) This observational study seeks to characterize and compare in-person versus TeleVisits. Fifty percent of participants will be provided computer equipment for their remote assessment and the other 50% will use their existing home-based equipment for this purpose. TeleVisit is a method for participants to connect to the research study team remotely, via video and audio connection either on their computer or iPad.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Are male or female and 18 years or older at the time of signing the informed consent
•2. Are able and willing to provide written informed consent
•3. Are English speaking
•4. Currently exhibit motor signs and symptoms of Huntington Disease
•5. Have a genetic diagnosis of HD with an expanded CAG repeat (greater than or equal to 36) in the huntingtin (HTT) gene at or before Screening/Baseline visit from a validated laboratory
•6. Have oral and written communication skills that are sufficient/adequate to complete all cognitive assessments
•7. Are ambulatory, but may use any assistive device or require help
•8. Are able to maintain stable medications for 30 days prior to Screening/Baseline through the second in-person visit
•9. Have a study partner available to help with technology and set-up and to attend all study visits
•10. Have the ability to get email on the device used for the study

Exclusion Criteria

•1. Are unable to complete cognitive or functional assessments due to inability to communicate
•2. Are unable to obtain satisfactory internet connection (i.e., internet connection must be stable and support the audio and video needs without freezing or interruption) at home or designated location, even with provided equipment
•3. Have inadequate space at home to assess 10 steps for gait assessments
•4. Have active suicidal ideation endorsed with a score of 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) if the ideation occurred within 1 year of Screening or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS if the attempt or acts were performed within 1 year of Screening/Baseline, or participants who, in the opinion of the Site Investigator (SI), present a serious risk of suicide.
•5. Have received gene therapy or an investigational drug within 30 days or 5 half-lives, whichever is longer, of the Screening/Baseline visit or plan to use an investigational drug during this study.

Locations (17)

University of Alabama at Birmingham, Department of Neurology

Birmingham, Alabama, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

University of California, San Diego

La Jolla, California, United States

Georgetown University

Washington D.C., District of Columbia, United States

University of South Florida, Huntington Disease Center of Excellence

Tampa, Florida, United States

Northwestern University Medical Center, Department of Neurology

Chicago, Illinois, United States

Rush University Medical Center

Chicago, Illinois, United States

Indiana University School of Medicine

Indianapolis, Indiana, United States

Hereditary Neurological Disease Center

Wichita, Kansas, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Key Dates

Start Date

September 22, 2022

Primary Completion Date

May 2, 2023

Completion Date

May 2, 2023

Last Updated

September 28, 2023

Enrollment

ACTUAL participants

Conditions

Huntington Disease

Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

NCT04012411

Huntington Disease

View study

RECRUITINGNA

Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)

NCT06414967

Huntington Disease

View study

RECRUITINGPHASE1/PHASE2

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

NCT05822908

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Development of the Virtual Unified Huntington's Disease Rating Scale

Inclusion Criteria

Exclusion Criteria

Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD)

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

IMarkHD: in Vivo Longitudinal Imaging of HD Pathology

Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease